Cost-effectiveness of artemisinin–naphthoquine versus artemether–lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-10-30

AUTHORS

Brioni R. Moore, Wendy A. Davis, Philip M. Clarke, Leanne J. Robinson, Moses Laman, Timothy M. E. Davis

ABSTRACT

BACKGROUND: A recent randomized trial showed that artemisinin-naphthoquine (AN) was non-inferior to artemether-lumefantrine (AL) for falciparum malaria and superior for vivax malaria in young Papua New Guinean children. The aim of this study was to compare the cost-effectiveness of these two regimens. METHODS: An incremental cost-effectiveness analysis was performed using data from 231 children with Plasmodium falciparum and/or Plasmodium vivax infections in an open-label, randomized, parallel-group trial. Recruited children were randomized 1:1 to receive once daily AN for 3 days with water or twice daily AL for 3 days given with fat. World Health Organisation (WHO) definitions were used to determine clinical/parasitological outcomes. The cost of transport between the home and clinic, plus direct health-care costs, served as a basis for determining each regimen's incremental cost per incremental treatment success relative to AL by Day 42 and its cost per life year saved. RESULTS: In the usual care setting, AN was more effective for the treatment of uncomplicated malaria in children aged 0.5-5.9 years. AL and AN were equally efficacious for the treatment of falciparum malaria, however AN had increased anti-malarial treatment costs per patient of $10.46, compared with AL. AN was the most effective regimen for treatment of vivax malaria, but had increased treatment costs of $14.83 per treatment success compared with AL. CONCLUSIONS: Whilst AN has superior overall efficacy for the treatment of uncomplicated malaria in PNG children, AL was the less costly regimen. An indicative extrapolation estimated the cost per life year saved by using AN instead of AL to treat uncomplicated malaria to be $12,165 for girls and $12,469 for boys (discounted), which means AN may not be cost-effective and affordable for PNG at current cost. However, AN may become acceptable should it become WHO prequalified and/or should donated/subsidized drug supply become available. More... »

PAGES

438

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12936-017-2081-8

DOI

http://dx.doi.org/10.1186/s12936-017-2081-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092450164

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29084540


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimalarials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Artemether, Lumefantrine Drug Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Artemisinins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Malaria, Falciparum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Malaria, Vivax", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Naphthoquinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Papua New Guinea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia", 
          "id": "http://www.grid.ac/institutes/grid.1012.2", 
          "name": [
            "School of Pharmacy, Curtin University of Technology, Perth, WA Australia", 
            "School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moore", 
        "givenName": "Brioni R.", 
        "id": "sg:person.01251142553.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251142553.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia", 
          "id": "http://www.grid.ac/institutes/grid.1012.2", 
          "name": [
            "School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davis", 
        "givenName": "Wendy A.", 
        "id": "sg:person.0701447021.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701447021.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1008.9", 
          "name": [
            "Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "Philip M.", 
        "id": "sg:person.0734456474.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, VIC Australia", 
          "id": "http://www.grid.ac/institutes/grid.1042.7", 
          "name": [
            "Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea", 
            "Burnet Institute, Parkville, Melbourne, VIC Australia", 
            "Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, VIC Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robinson", 
        "givenName": "Leanne J.", 
        "id": "sg:person.01073622365.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073622365.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea", 
          "id": "http://www.grid.ac/institutes/grid.417153.5", 
          "name": [
            "Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laman", 
        "givenName": "Moses", 
        "id": "sg:person.01177775000.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177775000.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia", 
          "id": "http://www.grid.ac/institutes/grid.1012.2", 
          "name": [
            "School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davis", 
        "givenName": "Timothy M. E.", 
        "id": "sg:person.07554175307.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07554175307.95"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1475-2875-13-363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047943951", 
          "https://doi.org/10.1186/1475-2875-13-363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2875-8-41", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051326669", 
          "https://doi.org/10.1186/1475-2875-8-41"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2875-12-433", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023058984", 
          "https://doi.org/10.1186/1475-2875-12-433"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd4573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002585744", 
          "https://doi.org/10.1038/nrd4573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/10899580-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004071643", 
          "https://doi.org/10.2165/10899580-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2875-9-336", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046841647", 
          "https://doi.org/10.1186/1475-2875-9-336"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-10-30", 
    "datePublishedReg": "2017-10-30", 
    "description": "BACKGROUND: A recent randomized trial showed that artemisinin-naphthoquine (AN) was non-inferior to artemether-lumefantrine (AL) for falciparum malaria and superior for vivax malaria in young Papua New Guinean children. The aim of this study was to compare the cost-effectiveness of these two regimens.\nMETHODS: An incremental cost-effectiveness analysis was performed using data from 231 children with Plasmodium falciparum and/or Plasmodium vivax infections in an open-label, randomized, parallel-group trial. Recruited children were randomized 1:1 to receive once daily AN for 3\u00a0days with water or twice daily AL for 3\u00a0days given with fat. World Health Organisation (WHO) definitions were used to determine clinical/parasitological outcomes. The cost of transport between the home and clinic, plus direct health-care costs, served as a basis for determining each regimen's incremental cost per incremental treatment success relative to AL by Day 42 and its cost per life year saved.\nRESULTS: In the usual care setting, AN was more effective for the treatment of uncomplicated malaria in children aged 0.5-5.9\u00a0years. AL and AN were equally efficacious for the treatment of falciparum malaria, however AN had increased anti-malarial treatment costs per patient of $10.46, compared with AL. AN was the most effective regimen for treatment of vivax malaria, but had increased treatment costs of $14.83 per treatment success compared with AL.\nCONCLUSIONS: Whilst AN has superior overall efficacy for the treatment of uncomplicated malaria in PNG children, AL was the less costly regimen. An indicative extrapolation estimated the cost per life year saved by using AN instead of AL to treat uncomplicated malaria to be $12,165 for girls and $12,469 for boys (discounted), which means AN may not be cost-effective and affordable for PNG at current cost. However, AN may become acceptable should it become WHO prequalified and/or should donated/subsidized drug supply become available.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12936-017-2081-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6727132", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6732355", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6730159", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6734158", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1030597", 
        "issn": [
          "1475-2875"
        ], 
        "name": "Malaria Journal", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "Papua New Guinean children", 
      "Artemisinin-naphthoquine", 
      "uncomplicated malaria", 
      "falciparum malaria", 
      "vivax malaria", 
      "Guinean children", 
      "treatment success", 
      "young Papua New Guinean children", 
      "life years", 
      "direct health care costs", 
      "incremental cost", 
      "World Health Organization definition", 
      "superior overall efficacy", 
      "Plasmodium vivax infection", 
      "parallel-group trial", 
      "treatment costs", 
      "usual care settings", 
      "incremental cost-effectiveness analysis", 
      "health care costs", 
      "cost-effectiveness analysis", 
      "parasitological outcomes", 
      "costly regimen", 
      "effective regimen", 
      "artemether-lumefantrine", 
      "vivax infection", 
      "PNG children", 
      "care settings", 
      "Organization definition", 
      "day 42", 
      "overall efficacy", 
      "malaria", 
      "Plasmodium falciparum", 
      "drug supply", 
      "regimen", 
      "treatment", 
      "children", 
      "trials", 
      "days", 
      "years", 
      "regimens", 
      "patients", 
      "clinic", 
      "lumefantrine", 
      "infection", 
      "falciparum", 
      "efficacy", 
      "outcomes", 
      "fat", 
      "boys", 
      "girls", 
      "aim", 
      "setting", 
      "home", 
      "current cost", 
      "study", 
      "success", 
      "data", 
      "cost", 
      "analysis", 
      "definition", 
      "basis", 
      "cost of transport", 
      "supply", 
      "PNG", 
      "transport", 
      "extrapolation", 
      "al", 
      "water", 
      "New Guinean children", 
      "daily AL", 
      "Health Organisation (WHO) definitions", 
      "regimen's incremental cost", 
      "incremental treatment success", 
      "anti-malarial treatment costs", 
      "Whilst AN", 
      "indicative extrapolation"
    ], 
    "name": "Cost-effectiveness of artemisinin\u2013naphthoquine versus artemether\u2013lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children", 
    "pagination": "438", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092450164"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12936-017-2081-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29084540"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12936-017-2081-8", 
      "https://app.dimensions.ai/details/publication/pub.1092450164"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_751.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12936-017-2081-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2081-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2081-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2081-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12936-017-2081-8'


 

This table displays all metadata directly associated to this object as RDF triples.

288 TRIPLES      22 PREDICATES      126 URIs      112 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12936-017-2081-8 schema:about N04db13084cab4a4abadebb8e9f751b97
2 N0ca07dc9e4b64e849b725fe4acd66b3f
3 N2b87035a725c4152ba65a2cc07e785b1
4 N478df08c8bf94f779509ba84a67d74c3
5 N575bec69c57c4f8aa8705c3a06444a09
6 N6491b77e112b4e56b78d8abed5c8b8e6
7 N71bb9281d4564f33b689f236cebeed83
8 N740a273b492241138e7deb528e341b7a
9 N7af6955a6896488f896f37b1117b39a1
10 N8df9dbc253ef4c209ebf032c9cb84137
11 N8f275310496340748dbee704026de6af
12 N9bef1fa57a744cf08613701e90eab506
13 Na12f474824cf4dd6bcfc6ec66ab9f8e4
14 Naa4265c650d24603a3c51b2f96f2c6d4
15 Ncac2f46294dc41a6b87322e1464df85f
16 Nd82a646f9ac5402dab27615ad2034436
17 Ne737e22271134a5ca9f005c767e31122
18 Nfd1ee6361375413bba66ee11ed052b89
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author Ne5cb7ab59ba143238943486ca2380465
22 schema:citation sg:pub.10.1038/nrd4573
23 sg:pub.10.1186/1475-2875-12-433
24 sg:pub.10.1186/1475-2875-13-363
25 sg:pub.10.1186/1475-2875-8-41
26 sg:pub.10.1186/1475-2875-9-336
27 sg:pub.10.2165/10899580-000000000-00000
28 schema:datePublished 2017-10-30
29 schema:datePublishedReg 2017-10-30
30 schema:description BACKGROUND: A recent randomized trial showed that artemisinin-naphthoquine (AN) was non-inferior to artemether-lumefantrine (AL) for falciparum malaria and superior for vivax malaria in young Papua New Guinean children. The aim of this study was to compare the cost-effectiveness of these two regimens. METHODS: An incremental cost-effectiveness analysis was performed using data from 231 children with Plasmodium falciparum and/or Plasmodium vivax infections in an open-label, randomized, parallel-group trial. Recruited children were randomized 1:1 to receive once daily AN for 3 days with water or twice daily AL for 3 days given with fat. World Health Organisation (WHO) definitions were used to determine clinical/parasitological outcomes. The cost of transport between the home and clinic, plus direct health-care costs, served as a basis for determining each regimen's incremental cost per incremental treatment success relative to AL by Day 42 and its cost per life year saved. RESULTS: In the usual care setting, AN was more effective for the treatment of uncomplicated malaria in children aged 0.5-5.9 years. AL and AN were equally efficacious for the treatment of falciparum malaria, however AN had increased anti-malarial treatment costs per patient of $10.46, compared with AL. AN was the most effective regimen for treatment of vivax malaria, but had increased treatment costs of $14.83 per treatment success compared with AL. CONCLUSIONS: Whilst AN has superior overall efficacy for the treatment of uncomplicated malaria in PNG children, AL was the less costly regimen. An indicative extrapolation estimated the cost per life year saved by using AN instead of AL to treat uncomplicated malaria to be $12,165 for girls and $12,469 for boys (discounted), which means AN may not be cost-effective and affordable for PNG at current cost. However, AN may become acceptable should it become WHO prequalified and/or should donated/subsidized drug supply become available.
31 schema:genre article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N66a698cadeb64c99b41627bc60acbb8e
35 Nb5187ed241aa4c89a79d64de10ba41c5
36 sg:journal.1030597
37 schema:keywords Artemisinin-naphthoquine
38 Guinean children
39 Health Organisation (WHO) definitions
40 New Guinean children
41 Organization definition
42 PNG
43 PNG children
44 Papua New Guinean children
45 Plasmodium falciparum
46 Plasmodium vivax infection
47 Whilst AN
48 World Health Organization definition
49 aim
50 al
51 analysis
52 anti-malarial treatment costs
53 artemether-lumefantrine
54 basis
55 boys
56 care settings
57 children
58 clinic
59 cost
60 cost of transport
61 cost-effectiveness analysis
62 costly regimen
63 current cost
64 daily AL
65 data
66 day 42
67 days
68 definition
69 direct health care costs
70 drug supply
71 effective regimen
72 efficacy
73 extrapolation
74 falciparum
75 falciparum malaria
76 fat
77 girls
78 health care costs
79 home
80 incremental cost
81 incremental cost-effectiveness analysis
82 incremental treatment success
83 indicative extrapolation
84 infection
85 life years
86 lumefantrine
87 malaria
88 outcomes
89 overall efficacy
90 parallel-group trial
91 parasitological outcomes
92 patients
93 regimen
94 regimen's incremental cost
95 regimens
96 setting
97 study
98 success
99 superior overall efficacy
100 supply
101 transport
102 treatment
103 treatment costs
104 treatment success
105 trials
106 uncomplicated malaria
107 usual care settings
108 vivax infection
109 vivax malaria
110 water
111 years
112 young Papua New Guinean children
113 schema:name Cost-effectiveness of artemisinin–naphthoquine versus artemether–lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children
114 schema:pagination 438
115 schema:productId N59ecb2ae399f40cc839fe8351689777c
116 N978b63d200c04a0e85c494f887789a4e
117 Ncd4f85ea411143ff8ffe566c2c41940b
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092450164
119 https://doi.org/10.1186/s12936-017-2081-8
120 schema:sdDatePublished 2022-01-01T18:45
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N505d3a575afa4ea78ecfa70dc68ac6ab
123 schema:url https://doi.org/10.1186/s12936-017-2081-8
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N04db13084cab4a4abadebb8e9f751b97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Papua New Guinea
129 rdf:type schema:DefinedTerm
130 N0ca07dc9e4b64e849b725fe4acd66b3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Fluorenes
132 rdf:type schema:DefinedTerm
133 N2b87035a725c4152ba65a2cc07e785b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 N478df08c8bf94f779509ba84a67d74c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Malaria, Vivax
138 rdf:type schema:DefinedTerm
139 N4dcbf4f9dd8c461ba011ec703b73be5d rdf:first sg:person.0734456474.38
140 rdf:rest Nb469066d04fc463c8233c6b56a154237
141 N505d3a575afa4ea78ecfa70dc68ac6ab schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N575bec69c57c4f8aa8705c3a06444a09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Cost-Benefit Analysis
145 rdf:type schema:DefinedTerm
146 N59ecb2ae399f40cc839fe8351689777c schema:name pubmed_id
147 schema:value 29084540
148 rdf:type schema:PropertyValue
149 N6491b77e112b4e56b78d8abed5c8b8e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Male
151 rdf:type schema:DefinedTerm
152 N64d1b438eb9f4acbbf0ff7cd77adc26c rdf:first sg:person.0701447021.64
153 rdf:rest N4dcbf4f9dd8c461ba011ec703b73be5d
154 N66a698cadeb64c99b41627bc60acbb8e schema:issueNumber 1
155 rdf:type schema:PublicationIssue
156 N71bb9281d4564f33b689f236cebeed83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Randomized Controlled Trials as Topic
158 rdf:type schema:DefinedTerm
159 N740a273b492241138e7deb528e341b7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Female
161 rdf:type schema:DefinedTerm
162 N7af6955a6896488f896f37b1117b39a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Infant
164 rdf:type schema:DefinedTerm
165 N888e4a7495dd4cca95ec594700cb81f7 rdf:first sg:person.07554175307.95
166 rdf:rest rdf:nil
167 N8ac5ad547162457296ffedddad561826 rdf:first sg:person.01177775000.99
168 rdf:rest N888e4a7495dd4cca95ec594700cb81f7
169 N8df9dbc253ef4c209ebf032c9cb84137 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Antimalarials
171 rdf:type schema:DefinedTerm
172 N8f275310496340748dbee704026de6af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Treatment Outcome
174 rdf:type schema:DefinedTerm
175 N978b63d200c04a0e85c494f887789a4e schema:name dimensions_id
176 schema:value pub.1092450164
177 rdf:type schema:PropertyValue
178 N9bef1fa57a744cf08613701e90eab506 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Artemether, Lumefantrine Drug Combination
180 rdf:type schema:DefinedTerm
181 Na12f474824cf4dd6bcfc6ec66ab9f8e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Naphthoquinones
183 rdf:type schema:DefinedTerm
184 Naa4265c650d24603a3c51b2f96f2c6d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Artemisinins
186 rdf:type schema:DefinedTerm
187 Nb469066d04fc463c8233c6b56a154237 rdf:first sg:person.01073622365.03
188 rdf:rest N8ac5ad547162457296ffedddad561826
189 Nb5187ed241aa4c89a79d64de10ba41c5 schema:volumeNumber 16
190 rdf:type schema:PublicationVolume
191 Ncac2f46294dc41a6b87322e1464df85f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Ethanolamines
193 rdf:type schema:DefinedTerm
194 Ncd4f85ea411143ff8ffe566c2c41940b schema:name doi
195 schema:value 10.1186/s12936-017-2081-8
196 rdf:type schema:PropertyValue
197 Nd82a646f9ac5402dab27615ad2034436 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Malaria, Falciparum
199 rdf:type schema:DefinedTerm
200 Ne5cb7ab59ba143238943486ca2380465 rdf:first sg:person.01251142553.60
201 rdf:rest N64d1b438eb9f4acbbf0ff7cd77adc26c
202 Ne737e22271134a5ca9f005c767e31122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Child, Preschool
204 rdf:type schema:DefinedTerm
205 Nfd1ee6361375413bba66ee11ed052b89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Drug Combinations
207 rdf:type schema:DefinedTerm
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
212 schema:name Clinical Sciences
213 rdf:type schema:DefinedTerm
214 sg:grant.6727132 http://pending.schema.org/fundedItem sg:pub.10.1186/s12936-017-2081-8
215 rdf:type schema:MonetaryGrant
216 sg:grant.6730159 http://pending.schema.org/fundedItem sg:pub.10.1186/s12936-017-2081-8
217 rdf:type schema:MonetaryGrant
218 sg:grant.6732355 http://pending.schema.org/fundedItem sg:pub.10.1186/s12936-017-2081-8
219 rdf:type schema:MonetaryGrant
220 sg:grant.6734158 http://pending.schema.org/fundedItem sg:pub.10.1186/s12936-017-2081-8
221 rdf:type schema:MonetaryGrant
222 sg:journal.1030597 schema:issn 1475-2875
223 schema:name Malaria Journal
224 schema:publisher Springer Nature
225 rdf:type schema:Periodical
226 sg:person.01073622365.03 schema:affiliation grid-institutes:grid.1042.7
227 schema:familyName Robinson
228 schema:givenName Leanne J.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073622365.03
230 rdf:type schema:Person
231 sg:person.01177775000.99 schema:affiliation grid-institutes:grid.417153.5
232 schema:familyName Laman
233 schema:givenName Moses
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177775000.99
235 rdf:type schema:Person
236 sg:person.01251142553.60 schema:affiliation grid-institutes:grid.1012.2
237 schema:familyName Moore
238 schema:givenName Brioni R.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251142553.60
240 rdf:type schema:Person
241 sg:person.0701447021.64 schema:affiliation grid-institutes:grid.1012.2
242 schema:familyName Davis
243 schema:givenName Wendy A.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701447021.64
245 rdf:type schema:Person
246 sg:person.0734456474.38 schema:affiliation grid-institutes:grid.1008.9
247 schema:familyName Clarke
248 schema:givenName Philip M.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38
250 rdf:type schema:Person
251 sg:person.07554175307.95 schema:affiliation grid-institutes:grid.1012.2
252 schema:familyName Davis
253 schema:givenName Timothy M. E.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07554175307.95
255 rdf:type schema:Person
256 sg:pub.10.1038/nrd4573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002585744
257 https://doi.org/10.1038/nrd4573
258 rdf:type schema:CreativeWork
259 sg:pub.10.1186/1475-2875-12-433 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023058984
260 https://doi.org/10.1186/1475-2875-12-433
261 rdf:type schema:CreativeWork
262 sg:pub.10.1186/1475-2875-13-363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047943951
263 https://doi.org/10.1186/1475-2875-13-363
264 rdf:type schema:CreativeWork
265 sg:pub.10.1186/1475-2875-8-41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051326669
266 https://doi.org/10.1186/1475-2875-8-41
267 rdf:type schema:CreativeWork
268 sg:pub.10.1186/1475-2875-9-336 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046841647
269 https://doi.org/10.1186/1475-2875-9-336
270 rdf:type schema:CreativeWork
271 sg:pub.10.2165/10899580-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004071643
272 https://doi.org/10.2165/10899580-000000000-00000
273 rdf:type schema:CreativeWork
274 grid-institutes:grid.1008.9 schema:alternateName Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
275 schema:name Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
276 rdf:type schema:Organization
277 grid-institutes:grid.1012.2 schema:alternateName School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia
278 schema:name School of Medicine and Pharmacology, University of Western Australia, Perth, WA Australia
279 School of Pharmacy, Curtin University of Technology, Perth, WA Australia
280 rdf:type schema:Organization
281 grid-institutes:grid.1042.7 schema:alternateName Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, VIC Australia
282 schema:name Burnet Institute, Parkville, Melbourne, VIC Australia
283 Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, VIC Australia
284 Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea
285 rdf:type schema:Organization
286 grid-institutes:grid.417153.5 schema:alternateName Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea
287 schema:name Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea
288 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...